Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
In Vivo · 2024
DOI: 10.21873/invivo.13648 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Akinori Minato und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; a-minato@med.uoeh-u.ac.jp. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; a-minato@med.uoeh-u.ac.jp.
- Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Urology, Kyushu Rosai Hospital, Kitakyushu, Japan.
Zitieren
APA
Minato, A., Ohno, D., Murooka, K., Okumura, Y., Takaba, T., Higashijima, K., Nagata, Y., Tomisaki, I., Harada, K., & Fujimoto, N. (2024). Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma. In Vivo. https://doi.org/10.21873/invivo.13648
Vancouver
Minato A, Ohno D, Murooka K, Okumura Y, Takaba T, Higashijima K, et al. Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma. In Vivo. 2024. doi:10.21873/invivo.13648
BibTeX
@article{Minato2024,
author = {Minato, Akinori and Ohno, Daichi and Murooka, Kazuki and Okumura, Yutaka and Takaba, Tomohisa and Higashijima, Katsuyoshi and Nagata, Yujiro and Tomisaki, Ikko and Harada, Kenichi and Fujimoto, Naohiro},
title = {Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13648}
}
EUVIMED